BioVentrix conducts first clinical application of Revivent TC System in Germany

19 December 2016 (Last Updated December 19th, 2016 18:30)

US-based medical device company BioVentrix has conducted the first clinical application of its closed-chest Revivent TC TransCatheter Ventricular Enhancement System in Germany.

US-based medical device company BioVentrix has conducted the first clinical application of its closed-chest Revivent TC TransCatheter Ventricular Enhancement System in Germany.

Designed for the less invasive ventricular enhancement (LIVE) procedure, the Revivent TC System serves as an alternative to conventional surgical ventricular restoration (SVR), by enabling a closed-chest approach.

The Revivent TC System is placed without sternotomy or ventriculotomy, thereby eliminating the need for cardiopulmonary bypass.

"This is the only minimally invasive technology which enables plication of scar tissue resulting in complete exclusion outside the LV cavity."

The system features a proprietary transcatheter delivery system designed to reduce volume of the left ventricle (LV) by placing anchors to separate scarred myocardial tissue from the left ventricle while restoring its more natural conical shape.

The Revivent TC System uses a hybrid endovascular technique performed in the hybrid cath lab which allows treatment of fragile patient population by eliminating the risks of open surgical intervention.

During the procedure, the physicians implanted two anchor pairs which remodelled the left ventricular  volume to improve pumping efficiency, decrease wall stress and ultimately resulting left ventricular volume reduction of 24%, which is considered as a significant improvement for a patient suffering from ischemic heart failure.

One of the interventional cardiologists who performed the procedure Dr Tobias Schmidt said: "The 24% volume reduction should directly impact the heart's pumping efficiency, which is a positive outcome for ischemic patients.

“That will result in an improvement in the patient's quality of life.

"This is the only minimally invasive technology which enables plication of scar tissue resulting in complete exclusion outside the LV cavity.”

Headquartered in San Ramon, California, BioVentrix is focused on developing and commercialising minimally invasive therapies for treating heart failure.